Document is current
Any future updates will be listed below
-
Authors
Newton, Hannah S https://orcid.org/0000-0002-6368-0803
Gawali, Vaibhavkumar S https://orcid.org/0000-0002-7917-4913
Chimote, Ameet A https://orcid.org/0000-0001-5163-0123
Lehn, Maria A
Palackdharry, Sarah M
Hinrichs, Benjamin H
Jandarov, Roman
Hildeman, David
Janssen, Edith M
Wise-Draper, Trisha M
Conforti, Laura https://orcid.org/0000-0002-3761-7595
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02641093 at ClinicalTrials.govnct02641093 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
PD1 blockade enhances K<sup>+</sup> channel activity, Ca<sup>2+</sup> signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer
https://doi.org/10.1136/jitc-2020-000844
809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival
https://doi.org/10.1136/jitc-2020-sitc2020.0809
Documents that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
PD1 blockade enhances K<sup>+</sup> channel activity, Ca<sup>2+</sup> signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer
https://doi.org/10.1136/jitc-2020-000844
809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival
https://doi.org/10.1136/jitc-2020-sitc2020.0809
-
Funding
Funding for this research was provided by:
Brandon C. Gromada Head & Neck Cancer Foundation
U.S. Department of Defense (Award No. W81XWH-17-1-0374)
Merck
National Cancer Institute (Award No. CA95286)
National Cancer Institute (Grant No. T32CA117846)
National Institutes of Health (Translational Science Award KL2 Training Grant TR0)
- License Information
